The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 3.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...
Repligen has returned to double-digit organic growth, with 2026 guidance for a 10%-14% revenue increase and margin improvement. Despite strong positioning in bioprocessing and a robust net cash ...
The latest price target for Repligen (NASDAQ:RGEN) was reported by Benchmark on July 7, 2026. The analyst firm set a price target for $185.00 expecting RGEN to rise to within 12 months (a possible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results